📊 Complete Technology Comparison
| Feature | Organ-on-Chip | Organoids | Digital Twin | In Silico / AI | Animal Models |
|---|---|---|---|---|---|
| Human Relevance | Excellent Human cells, physiological flow |
Excellent Human cells, 3D structure |
Good Based on human data |
Moderate Trained on human data |
Limited Species differences |
| Toxicity Prediction (DILI) | 87% Ewart et al., 2022 |
75-80% Varies by model |
70-80% Depends on training |
60-75% QSAR models |
47% Poor translation |
| Throughput | Medium ~100s/week |
High Scalable with automation |
Very High Unlimited simulations |
Very High Millions of compounds |
Low Weeks per study |
| Cost per Study | $10K-50K | $5K-30K | $1K-10K | $100-5K | $100K-5M |
| Timeline | 2-4 weeks | 4-12 weeks Growth time needed |
Hours-Days | Minutes-Hours | Months |
| FDA Acceptance | Yes ISTAND qualified |
Growing Case-by-case |
Yes PBPK accepted |
Limited Supportive data |
Yes Gold standard (historical) |
| Multi-Organ Capability | Yes Body-on-chip systems |
Emerging Assembloids |
Yes Full body simulation |
Yes PBPK models |
Yes Whole organism |
| Patient-Specific Testing | Yes iPSC-derived |
Yes Patient organoids |
Yes Individual modeling |
Limited Population-based |
No |
| Real-time Monitoring | Yes Integrated sensors |
Limited Endpoint assays |
Yes Continuous output |
N/A | Limited Blood draws, imaging |
| Immune System Modeling | Emerging Immune cells added |
Emerging Co-culture models |
Good PK/PD integration |
Limited | Good Full immune system |
| Best Use Case | ADME/Tox Drug safety, PK |
Disease Modeling Cancer, genetic diseases |
Trial Design Dosing, populations |
Early Screening Lead optimization |
Regulatory Req. Legacy compliance |
🎯 Which Technology Should You Use?
Answer a few questions to get a personalized recommendation.
1. What's your primary goal?
2. What's your timeline?
3. What's your budget range?
4. Do you need FDA submission support?
5. Which organ/system are you studying?
✨ Our Recommendation
Organ-on-Chip
Best fit for your requirements
Why this technology:
- High predictive accuracy for toxicity (87% for DILI)
- FDA-qualified through ISTAND program
- Real-time monitoring capabilities
Recommended providers: Emulate, CN Bio, MIMETAS
💡 Quick Decision Guide
- Need FDA submission data? → Organ-on-Chip (ISTAND qualified)
- Studying cancer/tumors? → Patient-derived Organoids
- Early-stage screening 1000s of compounds? → In Silico / AI
- Optimizing clinical trial design? → Digital Twin
- Best combination: AI screening → Organ-chip validation → Clinical trials